Short-term efficacy of cetuximab-contained regimen on patients with advanced gastric and esophageal cancer / 国际肿瘤学杂志

ABSTRACT

Few studies of cetuximab on patients with gastric and esophageal cancer were available now.The disease control rate was 72.7%～92%,OS was 9.5～16.6months,PFS/was 6.2～11 months among first-line setting with cetuximab-contained regimens.And cetuximab shown in second-line regimen setting overcome the resistance of irinotecan and docetaxel.The pCR was 13%～65% when cetuximab was used as induction treatment combined with concurrent chemoradiation.18F-FDG-PET was a potential method to predictthe efficacy of cetuximab-contained regimens,however,status of Kras gene had no predictive value.